Neurosterix

CompanySwitzerland

Neurosterix develops one asset, in phase 1 (NTX-253 in schizophrenia). Mostly small molecule; based in Switzerland.

1
Asset
Furthest stage
Phase 1
0
Trials
1
Signal

Pipeline

1
  • NTX-253

    Allosteric modulator for schizophrenia

    Phase 1, Small molecule, schizophrenia

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Signals1
  • Similar companies6

Intelligence